【摘要】 目的:分析美西律联合参松养心胶囊对非ST段抬高型心肌梗死(NSTEMI)伴发心律失常患者疗效和心功能的影响。方法:将本院2015年6月至2018年6月178例NSTEMI伴发心律失常的门诊患者为研究对象,根据随机平行对照设计和简单随机分组方法,将患者分为对照组应用美西律治疗,研究组给予美西律联合参松养心胶囊治疗,两组各89例。比较两组患者临床疗效和治疗前后心电图指标、心功能指标变化及治疗期间不良反应发生情况的差异。结果:研究组治疗总有效率为97.75%,较对照组的86.52%明显增高(P<0.05)。相比治疗前,两组患者治疗后窦性心搏RR间期标准差(SDNN)及RR间期平均值标准差(SDANN)均显著增高(P<0.05),但研究组治疗后水平与对照组比较,并无显著性差异(P>0.05)。与治疗前相比,两组患者治疗后左心室射血分数(LVEF)、左心室收缩期内径(LVDs)及左心室舒张期内径(LVDd)的水平均显著增高;相比对照组,研究组治疗后水平增高更为明显(P<0.05)。研究组治疗期间不良反应发生率为3.37%,与对照组的6.74%比较,并无显著性差异(P>0.05)。结论:应用美西律联合参松养心胶囊治疗可有效改善NSTEMI伴发心律失常患者的临床疗效,对改善患者心功能、抗心律失常具有重要作用,且不会引起严重不良反应,提示该疗法具有良好的用药安全性,值得临床应用。更多还原

【Abstract】 Objective: To analyze the effect of mexiletine combined with Shensong Yangxin capsule on therapeutic effect and cardiac function in patients with non-ST-segment elevation myocardial infarction(NSTEMI) complicated with arrhythmia. Methods: 178 NSTEMI outpatients with arrhythmia from June 2015 to June 2018 in our hospital were selected as the research subjects. According to the randomized parallel control design and simple random grouping method, the patients were divided into control group treated with mexiletine and study group treated with mexiletine combined with Shensong Yangxincapsule, with 89 cases in each group. The clinical efficacy, electrocardiogram indexes, cardiac function indexes before and after treatment and adverse reactions during treatment were compared between the two groups. Results: The total effective rate of the study group was 97.75%, which was significantly increased compared with 86.52% of the control group(P<0.05). Compared with before treatment, standard diviation of NN intervals(SDNN) and standard diviation average of NN intervals(SDANN) were significantly increased in both groups after treatment(P<0.05), but there was no significant difference between the study group and the control group after treatment(P>0.05). Compared with before treatment, the levels of left ventricular ejection fraction(LVEF), left ventricular systolic diameter(LVDs) and left ventricular diastolic diameter(LVDd) in the two groups were significantly increased after treatment, and the levels in the study group were significantly increased compared with control group after treatment(P<0.05). The incidence of adverse reactions was 3.37% in the study group and 6.74% in the control group, which showed no significant difference between the two groups(P>0.05). Conclusion: Mexiletine combined with Shensong Yangxin capsule can effectively improve the clinical efficacy of NSTEMI patients with arrhythmia. It plays an important role in improving cardiac function and anti-arrhythmia, and does not cause serious adverse reactions. It suggests that this therapy has good drug safety and is worthy of clinical application.更多还原